A new clinical trial is set to investigate the potential of 40 Hz and 100 Hz flickering light devices to address insomnia symptoms in individuals diagnosed with Parkinson’s disease. With sponsorship from Jiangsu Province Nanjing Brain Hospital and The Eye Hospital of Wenzhou Medical University, this study is preparing to enroll participants. This research could mark a significant step forward in non-invasive device-based therapies for sleep disturbances commonly associated with neurodegenerative disorders.
In this article:
- What changed?
- How does Parkinson’s disease impact sleep?
- What is the role of flickering light devices in therapy?
- Who is conducting the research?
- Frequently asked questions
- Conclusion
- Disclaimer
- Announcement and source link
What changed?
The clinical trial, titled “40 Hz Flickering for Insomnia in Parkinson’s Disease,” was added to the medical research database with a status of “not yet recruiting.” This development signals the intention to explore innovative non-invasive solutions for managing symptoms of insomnia, a common but underexplored secondary symptom of Parkinson’s disease. The devices under trial, a 40 Hz flicker light and a 100 Hz flicker light, represent a technology-forward approach to managing sleep disturbances associated with neurodegenerative conditions.
How does Parkinson’s disease impact sleep?
Insomnia and other sleep disturbances are frequent challenges for individuals living with Parkinson’s disease. They can stem from the progression of the disease, motor symptoms, or medication schedules. These issues are often overlooked in treatment plans despite having a significant impact on patients’ quality of life.
The introduction of device-based interventions, like flickering light therapy, aligns with growing interest in modalities that aim to improve neurological functions through non-invasive methods. By addressing patients’ sleep patterns, such trials may improve overall care and offer new avenues for managing Parkinson’s-related complications.
What is the role of flickering light devices in therapy?
Flickering light therapy at specific frequencies has gained attention in neuroscience as a potential tool for modulating brain activity. The 40 Hz frequency, in particular, has been noted for its potential to engage neural circuits. Such therapies may influence brain functions related to sleep regulation.
In this trial, the researchers aim to validate whether sustained exposure to 40 Hz or 100 Hz flickering simulations can induce measurable improvements in insomnia symptoms for Parkinson’s patients. If successful, these interventions might provide practical, device-based therapies that work complementarily with existing pharmacological and behavioral interventions.
Who is conducting the research?
The trial is sponsored by Jiangsu Province Nanjing Brain Hospital and The Eye Hospital of Wenzhou Medical University, both of which are noted for their focus on bridging clinical care and innovative medical research. Their involvement underscores the legitimacy and collaborative efforts necessary for advancing such specialized interventions.
As trials advance, regulatory scrutiny will ensure the devices comply with performance and safety requirements consistent with medical standards. The present announcement signals the early stages of this protocol, informing the public and medical community about the ongoing exploration of this technology.
Frequently Asked Questions
-
What is the status of this clinical trial?
The trial is currently labeled as “not yet recruiting,” meaning participant enrollment has not yet commenced.
-
What conditions are being investigated?
Parkinson’s disease and insomnia are the primary conditions targeted in this study, specifically focusing on alleviating sleep disturbances linked to Parkinson’s.
-
What devices are involved?
The study will test two devices: a 40 Hz flicker light device and a 100 Hz flicker light device.
Conclusion
Parkinson’s disease often brings complex symptoms like insomnia, complicating patient care. The upcoming trial examining flickering light therapy devices represents a significant step in exploring innovative, non-invasive therapies for these challenges. Healthcare professionals, researchers, and device manufacturers should monitor this study for potential implications on future treatment guidelines.
Disclaimer
This article is for informational purposes only and does not constitute legal, clinical, or regulatory advice. Professionals should consult appropriate guidelines and legal resources for decision-making.
Announcement and source link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07323121?term=medical+device